Advertisement

Other treatments

Chapter
  • 1.9k Downloads

Abstract

Several depression-focused psychotherapies [1] have been developed to be time-limited treatments. They have an explicit goal of helping the individual achieve rapid relief of depressive symptoms, inasmuch as they are treatments comparable to pharmacotherapy in time course and efficacy. Furthermore, by emphasizing short-term goals, these therapies capitalize on the acute nature of many episodes of depression. Shared features of the depression-focused psychotherapies include their specific linkage of a theoretical model of phenomenology with strategies for symptom reduction, with specification of methods to facilitate training and enhance fidelity, and with acceptance of the need to identify observable and measurable goals and outcomes. The major types of time-limited depression-focused therapies that have reliably established comparability to antidepressant medications in RCTs include cognitive therapy (CBT) [2] and IPT [3]. The particular theoretical orientation of each model of treatment also yields predictions about specific outcomes, such as the effects of CBT on measures of dysfunctional attitudes or IPT on measures of social adjustment. Finally, these therapies share several pragmatic features, including their compatibility for use in combination with pharmacotherapy and their suitability for use by therapists with a range of backgrounds and training.

Keywords

Transcranial Magnetic Stimulation Deep Brain Stimulation Vagus Nerve Stimulation Sham Acupuncture Dysfunctional Attitude 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Friedman ES, Thase ME. Depression-focused psychotherapies. In:Treatment of Psychiatric Disorders, Vol 2, 4th edition. Edited by GO Gabbard. Washington, DC: American Psychiatric Press, Inc, 2007; 409–431.Google Scholar
  2. 2.
    Beck AT, Rush AJ, Shaw BF, et al. Cognitive Therapy of Depression. New York: Guilford, 1979.Google Scholar
  3. 3.
    Klerman GL, Weissman MM, Rounsaville BJ, et al. Interpersonal Psychotherapy of Depression. New York: Basic Books, 1984.Google Scholar
  4. 4.
    Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006; 188:46–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Friedman ES, Wright JH, Jarrett RB, et al. Combining cognitive therapy and medication for mood disorders. Psychiatr Ann 2006; 36:320–328.Google Scholar
  6. 6.
    Szigethy EM, Friedman ES. Combined psychotherapy and pharmacotherapy. In: Comprehensive Textbook of Psychiatry IX. Edited by HI Kaplan & BJ Zaddock. Baltimore, MD: Williams & Wilkins, 2009: in press.Google Scholar
  7. 7.
    Pampelloma S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61:714–719.CrossRefGoogle Scholar
  8. 8.
    AHCPR Depression Guideline Panel. Depression in Primary Care, Vol 1. Detection and diagnosis. Clinical practice guideline 5. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993.Google Scholar
  9. 9.
    American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(Suppl 4):1–45.Google Scholar
  10. 10.
    Mayberg HS. Modulating dysfunctional limbic–cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65:193–207.PubMedCrossRefGoogle Scholar
  11. 11.
    Goldapple K, Segal Z, Garson C, et al. Modulation of cortical–limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61:34–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Butler R, Hatcher S, Price J, et al. Depression in adults: psychological treatments and care pathways. BMJ Clin Evidence 2007; 1016:1–18.Google Scholar
  13. 13.
    Prudic J, Olfson M, Marcus SC, et al. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004; 55:301–312.PubMedCrossRefGoogle Scholar
  14. 14.
    Husain MM, Rush AJ, Fink M, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004; 65:485–491.PubMedCrossRefGoogle Scholar
  15. 15.
    Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the consortium for research in electroconvulsive therapy (CORE). Arch Gen Psychiatry 2006; 63:1337–1344.PubMedCrossRefGoogle Scholar
  16. 16.
    UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799–808.CrossRefGoogle Scholar
  17. 17.
    Pagnin D, de Queiroz V, Pini S. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004; 20:13–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Weiner RD. Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, 2nd edition. Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Publishing, Inc, 2001.Google Scholar
  19. 19.
    Scott AIF. The ECT Handbook: The Third Report of the Royal College of Psychiatrists’ Special Committee on ECT (Council Report CR128), 2nd edition. London, UK; Royal College of Psychiatry 2005.Google Scholar
  20. 20.
    Lisenby SH. Electroconvulsive therapy for depression. N Eng J Med 2007; 357:1939–1945.CrossRefGoogle Scholar
  21. 21.
    Partonen T, Magnusson A (eds). Seasonal Affective Disorder. Practice and Research. Oxford, UK: Oxford University Press, 2001.Google Scholar
  22. 22.
    Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005; 162:656–662.PubMedCrossRefGoogle Scholar
  23. 23.
    Lam RW. Seasonal Affective Disorder and Beyond. Light Treatment for SAD and nonSAD conditions. Washington, DC: American Psychiatric Press, 1998.Google Scholar
  24. 24.
    Epperson CN, Terman M, Terman JS, et al. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. J Clin Psychiatry 2004; 65:421–425.PubMedCrossRefGoogle Scholar
  25. 25.
    Rosenthal NE, Blehar MC. Seasonal Affective Disorders and Phototherapy. New York: Guilford, 1989.Google Scholar
  26. 26.
    Lewy AJ, Wehr TA, Goodwin DA, et al. Light suppresses melatonin secretion in humans. Science 1980; 210:1267–1269.PubMedCrossRefGoogle Scholar
  27. 27.
    Lam RW, Tam EM, Yatham LN, et al. Seasonal depression: the dual vulnerability hypothesis revisited. J Affect Disord 2001; 63:123–132.PubMedCrossRefGoogle Scholar
  28. 28.
    Seminowicz DA, Mayberg HS, McIntosh AR, et al. Limbic–frontal circuitry in major depression: a path modeling meta-analysis. Neuroimage 2004; 22:409–418.PubMedCrossRefGoogle Scholar
  29. 29.
    Shuchman M. Approving the vagus-nerve stimulator for depression. N Engl J Med 2007; 356:1604–1607.PubMedCrossRefGoogle Scholar
  30. 30.
    Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58:347–354.PubMedCrossRefGoogle Scholar
  31. 31.
    Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment resistant depression: efficacy, side effects and predictors of outcome. Neuropsychopharmacology 2001; 25:713–728.PubMedCrossRefGoogle Scholar
  32. 32.
    George MS, Rush AJ, Marengell LA, et al. One-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005; 58:364–373.PubMedCrossRefGoogle Scholar
  33. 33.
    Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus-nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005; 66:1097–1104.PubMedCrossRefGoogle Scholar
  34. 34.
    Janicak PG, O’Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry 2008; 69:222–232.PubMedCrossRefGoogle Scholar
  35. 35.
    Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Anderson I, Ferrier I, Baldwin R, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343–396.PubMedCrossRefGoogle Scholar
  37. 37.
    Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45:651–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Dunn AL, Trivedi MH, Kampert JB, et al. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005; 28:140–141.CrossRefGoogle Scholar
  39. 39.
    Blumenthal JA, Sherwood A, Rogers SD, et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study – rationale, design, and methodological issues. Clin Trials 2007; 4:548–559.PubMedCrossRefGoogle Scholar
  40. 40.
    Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000; 62:633–638.PubMedGoogle Scholar
  41. 41.
    Trivedi MH, Greer TL, Grannemann BD, et al. Exercise as an augmentation strategy. Psychiatr Pract 2006; 12:205–213.CrossRefGoogle Scholar
  42. 42.
    Lawlor DA, Hopter SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 2001; 322:1–8.CrossRefGoogle Scholar
  43. 43.
    Linde K, Ramirez G, Cynthia D, et al. St John’s wort for depression – an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313:253–258.PubMedCrossRefGoogle Scholar
  44. 44.
    Fava M, Alpert J, Nierenberg AA, et al. A double-blind, randomized trial of St John’s wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25:441–447.PubMedCrossRefGoogle Scholar
  45. 45.
    Shelton RC, Keller MB, Gelenberg AJ, et al. Effectiveness of St. John’s Wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978–1986.PubMedCrossRefGoogle Scholar
  46. 46.
    Gelenberg AJ, Shelton RC, Crits-Christoph P, et al. The effectiveness of St. John’s Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry 2004; 65:1114–1119.PubMedCrossRefGoogle Scholar
  47. 47.
    Hypericum Depression Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder. JAMA 2002; 287:1807–1814.CrossRefGoogle Scholar
  48. 48.
    Kasper S, Anghelescu IG, Szegedi A, et al. Superior efficacy of St John’s wort extract WS 55 70 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 2006; 4:14.PubMedCrossRefGoogle Scholar
  49. 49.
    Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002; 159:1361–1366.PubMedCrossRefGoogle Scholar
  50. 50.
    Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003; 160:996–998.PubMedCrossRefGoogle Scholar
  51. 51.
    Sontrop J, Campbell MK. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med 2006; 42:4–13.PubMedCrossRefGoogle Scholar
  52. 52.
    Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68:1056–1061.PubMedCrossRefGoogle Scholar
  53. 53.
    Appleton KM, Hayward RC, Gunnell D, et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2007; 84:1308–1316.Google Scholar
  54. 54.
    Allen JJB. Depression and acupuncture: a controlled clinical trial. Elements Health Centre 2000; 17:1–4.Google Scholar
  55. 55.
    Allen JJB, Schnyer RN, Hitt SK. The efficacy of acupuncture in the treatment of major depression in women. Psychol Sci 1998; 9:397–401.CrossRefGoogle Scholar
  56. 56.
    Smith CA, Hay PP. Acupuncture for depression. Cochrane Database System Rev 2005; (2): CD004046.Google Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  1. 1.PittsburghUSA

Personalised recommendations